Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 11Multiple Myeloma 7Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Ovarian Neoplasms 2Neurofibrosarcoma 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Congenital Abnormalities 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1

Interventions

Sorafenib 20Bevacizumab 7pembrolizumab 5Oxaliplatin 5Melphalan 5Leucovorin 5Irinotecan 5Nivolumab 4Ipilimumab 4Fluorouracil 4Cyclophosphamide 4Capecitabine 4fludarabine 3Sirolimus 3Radiosurgery 3Gemcitabine 3Filgrastim 3Carboplatin 3toripalimab 2spartalizumab 2regorafenib 2pazopanib 2lenvatinib 2ixabepilone 2durvalumab 2atezolizumab 2Vorinostat 2Thiotepa 2Temozolomide 2Sirtuins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Liver Neoplasms × selinexor × Clear all
NCT05093608 2022-10-17

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
2 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡